Market Research Life Sciences Market Research Pharmaceuticals Market Research Therapeutic Area Market Research Renal Market Research

Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031

Best Price Guarantee Length Publisher Published Date SKU
from $3,995 36 Pages GlobalData May, 2022 GBDT17223112
Best Price Guarantee
Price from $3,995
Length 36 Pages
Publisher GlobalData
Published Date May, 2022
SKU GBDT17223112

Chronic Kidney Disease Epidemiology Analysis and Forecast, 2021-2031

Summary

Chronic kidney disease (CKD) (ICD-10 = N18) is a condition characterized by a gradual loss of kidney function over time. This leads to the accumulation of excess fluid and waste in the body. In the early stages, CKD is a largely asymptomatic condition. As the disease progresses, the symptoms worsen and eventually lead to kidney failure (Centers for Disease Control and Prevention, 2022). Advanced chronic kidney disease can cause dangerous levels of fluid, electrolytes, and wastes to build up in the body (Mayo Clinic, 2021). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease Improving Global Outcomes (KDIGO) classification system is considered to be the standard for GFR measurement and diagnosis of CKD (Levin et al., 2013). This report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).

The report includes a 10-year epidemiology forecast for the total prevalent cases and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The following data describes epidemiology of CKD. In the 7MM, GlobalData epidemiologists forecast an increase in the total prevalent cases of CKD from 103,485,844 cases of CKD in 2021 to 114,351,930 cases of CKD in 2031, with an AGR of 1.05% during the forecast period. The diagnosed prevalent cases of CKD in the 7MM are expected to increase from 18,135,434 cases in 2021 to 19,917,590 cases in 2030, with an AGR of 0.98% during the forecast period. Women accounted for more total and diagnosed prevalent cases of CKD than men in the 7MM and it predominantly affects older adults. These findings are in line with the GlobalData estimates and these trends are reflected in GlobalData’s forecast for the total and diagnosed prevalent cases for the 7MM.

Scope

  • The Chronic Kidney Disease (CKD) Epidemiology Report provides an overview of the risk factors and global trends of CKD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of CKD. The total and diagnosed prevalent cases of CKD are further segmented by age (18 years and older), sex, and stage (stage I, stage II, stage IIIa, stage IIIb, stage IV, and stage V) in these markets. Diagnosed prevalent cases of CKD are further segmented by dialysis-dependent (including both hemodialysis and peritoneal dialysis) and non-dialysis dependent. The model associated with the report also provides the diagnosed prevalent cases of CKD further segmented by hyperparathyroidism, hyperphosphatemia, and hyperkalemia among dialysis-dependent and non-dialysis-dependent cases.
  • The CKD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Buy

The Chronic Kidney Disease (CKD) Epidemiology series will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global CKD market.
  • Quantify patient populations in the global CKD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CKD therapeutics in each of the markets covered.
  • Understand magnitude of CKD population by subtype, digital vasculopathy, and other internal organ involvement.


    • 1 Chronic Kidney Disease: Executive Summary
    1.1 Catalyst
    1.2 Related Reports
    1.3 Upcoming Reports
    2 Epidemiology
    2.1 Disease Background
    2.2 Risk Factors and Comorbidities
    2.3 Global and Historical Trends
    2.4 7MM Forecast Methodology
    2.4.1 Sources
    2.4.2 Forecast Assumptions and Methods
    2.4.3 Total Prevalent Cases of CKD
    2.4.4 Total Prevalent Cases of CKD by Stage
    2.4.5 Diagnosed Prevalent Cases of CKD
    2.4.6 Diagnosed Prevalent Cases of CKD by Stage
    2.4.7 Diagnosed Prevalent Cases of CKD Based on Dialysis Dependence
    2.5 Epidemiological Forecast for CKD (2021-31)
    2.5.1 Total Prevalent Cases of CKD
    2.5.2 Total Prevalent Cases of CKD by Stage
    2.5.3 Diagnosed Prevalent Cases of CKD
    2.5.4 Age-Specific Diagnosed Prevalent Cases of CKD
    2.5.5 Sex-Specific Diagnosed Prevalent Cases of CKD
    2.5.6 Diagnosed Prevalent Cases of CKD by Stage
    2.5.7 Diagnosed Prevalent Cases of CKD by Dialysis Dependence
    2.6 Discussion
    2.6.1 Epidemiological Forecast Insight
    2.6.2 COVID-19 Impact
    2.6.3 Limitations of the Analysis
    2.6.4 Strengths of the Analysis
    3 Appendix
    3.1 Bibliography
    3.2 About the Authors
    3.2.1 Epidemiologist
    3.2.2 Reviewers
    3.2.3 Global Director of Therapy Analysis and Epidemiology
    3.2.4 Global Head and EVP of Healthcare Operations and Strategy
    Contact Us
    List of Tables
    Table 1: Summary of updated data types
    Table 2: KDIGO classification of CKD
    Table 3: Risk factors and comorbid conditions associated with CKD
    List of Figures
    Figure 1: 7MM, total prevalent cases of CKD, both sexes, N, ages ≥18 years, 2021 and 2031
    Figure 2: 7MM, diagnosed prevalent cases of CKD, both sexes, N, ages ≥18 years, 2021 and 2031
    Figure 3: 7MM, diagnosed prevalence of CKD (%), men, ages ≥18 years, 2021
    Figure 4: 7MM, sources used and not used to forecast the total and diagnosed prevalent cases of CKD
    Figure 5: 7MM, sources used to forecast the total prevalent cases of CKD by stage
    Figure 6: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by stage
    Figure 7: 7MM, sources used to forecast the diagnosed prevalent cases of CKD by dialysis dependence
    Figure 8: 7MM, total prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021
    Figure 9: 7MM, total prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021
    Figure 10: 7MM, diagnosed prevalent cases of CKD, N, both sexes, ages ≥18 years, 2021
    Figure 11: 7MM, diagnosed prevalent cases of CKD by age group, N, both sexes, 2021
    Figure 12: 7MM, diagnosed prevalent cases of CKD by sex, N, ages ≥18 years, 2021
    Figure 13: 7MM, diagnosed prevalent cases of CKD by stage, N, both sexes, ages ≥18 years, 2021
    Figure 14: 7MM, diagnosed prevalent cases of CKD by dialysis dependence, N, both sexes, ages ≥18 years, 2021
    Figure 15: 7MM, diagnosed prevalent cases of CKD based on dialysis-dependent subtype, N, both sexes, ages ≥18 years, 2021

    $3,995
    $7,990
    $11,985

    Research Assistance

    US: 800.298.5699
    Int'l: +1.240.747.3093
    Live help
    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Other tasks

    Cookie Settings